Triple-Negative Breast Cancer: Early Assessment with 18F-FDG PET/CT During Neoadjuvant Chemotherapy Identifies Patients Who Are Unlikely to Achieve a Pathologic Complete Response and Are at a High Risk of Early Relapse

被引：74

作者：

Groheux, David ^{[1
,2
]}

Hindie, Elif ^{[2
]}

Giacchetti, Sylvie ^{[3
]}

Delord, Marc ^{[4
]}

Hamy, Anne-Sophie ^{[3
]}

de Roquancourt, Anne ^{[6
]}

Vercellino, Laetitia

Berenger, Nathalie

Marty, Michel ^{[3
,5
]}

Espie, Marc ^{[3
]}

机构：

[1] Hop St Louis, AP HP, Nucl Med Serv, Dept Nucl Med, F-75475 Paris 10, France

[2] Univ Paris 07, IUH, Doctoral Sch, B2T, Paris, France

[3] Hop St Louis, Dept Med Oncol, Breast Dis Unit, F-75475 Paris 10, France

[4] Inst Univ Hematol, Dept Biostat & Bioinformat, Paris, France

[5] St Louis Univ Hosp, Ctr Therapeut Innovat, Paris, France

[6] Hop St Louis, Dept Pathol, F-75475 Paris 10, France

来源：

JOURNAL OF NUCLEAR MEDICINE | 2012年 / 53卷 / 02期

关键词：

F-18-FDG PET/CT; triple-negative breast cancer; neoadjuvant chemotherapy; metabolic response; prognosis; POSITRON-EMISSION-TOMOGRAPHY; INTENSIFICATION; LYMPHOMA; THERAPY; INTERIM;

D O I：

10.2967/jnumed.111.094045

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Triple-negative breast cancer, an aggressive subtype, represents 15% of invasive breast tumors. This prospective study investigated whether early changes in F-18-FDG tumor uptake during neoadjuvant chemotherapy (NAC) can predict outcomes. Methods: Twenty (MO) patients underwent F-18-FDG PET/CT at baseline and after the second cycle. NAC was continued irrespective of PET results. Results: At surgery, 6 patients had a pathologic complete response, whereas 14 had residual tumor. Four patients showed early relapse (in the 2 y after surgery). There were 11 metabolic responders and 9 nonresponders using a 42% decrease in maximum standardized uptake value as a cutoff. In nonresponding patients, the risk of residual tumor at surgery was 100% (vs. 45% in responders; P = 0.014), and the risk of early relapse was 44% (vs. 0%; P = 0.024). Conclusion: A less than 42% decrease in F-18-FDG uptake at 2 cycles means residual tumor at the end of NAC and a high risk of early relapse.

引用

页码：249 / 254

页数：6

共 20 条

[1] Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters [J].

Basu, Sandip ;

Chen, Wengen ;

Tchou, Julia ;

Mavi, Ayse ;

Cermik, Tevfik ;

Czerniecki, Brian ;

Schnall, Mitchell ;

Alavi, Abass .

CANCER, 2008, 112 (05) :995-1000

[2] [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy [J].

Berriolo-Riedinger, Alina ;

Touzery, Claude ;

Riedinger, Jean-Marc ;

Toubeau, Michel ;

Coudert, Bruno ;

Arnould, Laurent ;

Boichot, Christophe ;

Cochet, Alexandre ;

Fumoleau, Pierre ;

Brunotte, Francois .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (12) :1915-1924

[3] The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes [J].

Carey, Lisa A. ;

Dees, E. Claire ;

Sawyer, Lynda ;

Gatti, Lisa ;

Moore, Dominic T. ;

Collichio, Frances ;

Ollila, David W. ;

Sartor, Carolyn I. ;

Graham, Mark L. ;

Perou, Charles M. .

CLINICAL CANCER RESEARCH, 2007, 13 (08) :2329-2334

[4]

Edge S.B., 2010, AJCC cancer staging manual, V649

[5] Triple-Negative Breast Cancer [J].

Foulkes, William D. ;

Smith, Ian E. ;

Reis-Filho, Jorge S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (20) :1938-1948

[6] Early interim 2-[18F]Fluoro-2-Deoxy-D-Glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma:: A report from a joint Italian-Danish study [J].

Gallamini, Andrea ;

Hutchings, Martin ;

Rigacci, Luigi ;

Specht, Lena ;

Merli, Francesco ;

Hansen, Mads ;

Patti, Caterina ;

Loft, Annika ;

Di Raimondo, Francesco ;

D'Amore, Francesco ;

Biggi, Alberto ;

Vitolo, Umberto ;

Stelitano, Caterina ;

Sancetta, Rosario ;

Trentin, Livio ;

Luminari, Stefano ;

Iannitto, Emilio ;

Viviani, Simonetta ;

Pierri, Ivana ;

Levis, Alessandro .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (24) :3746-3752

[7] Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses [J].

Gallamini, Andrea ;

Patti, Caterina ;

Viviani, Simonetta ;

Rossi, Andrea ;

Fiore, Francesca ;

Di Raimondo, Francesco ;

Cantonetti, Maria ;

Stelitano, Caterina ;

Feldman, Tatyana ;

Gavarotti, Paolo ;

Sorasio, Roberto ;

Mule, Antonino ;

Leone, Monica ;

Rambaldi, Alessandro ;

Biggi, Alberto ;

Barrington, Sally ;

Fallanca, Federico ;

Ficola, Umberto ;

Chauvie, Stephane ;

Gianni, Alessandro Massimo .

BRITISH JOURNAL OF HAEMATOLOGY, 2011, 152 (05) :551-560

[8] Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease [J].

Gralow, Julie R. ;

Burstein, Harold J. ;

Wood, William ;

Hortobagyi, Gabriel N. ;

Gianni, Luca ;

Von Minckwitz, Gunter ;

Buzdar, Aman U. ;

Smith, Ian E. ;

Symmans, William F. ;

Singh, Baljit ;

Winer, Eric P. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (05) :814-819

[9] Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer [J].

Groheux, David ;

Giacchetti, Sylvie ;

Moretti, Jean-Luc ;

Porcher, Raphael ;

Espie, Marc ;

Lehmann-Che, Jacqueline ;

de Roquancourt, Anne ;

Hamy, Anne-Sophie ;

Cuvier, Caroline ;

Vercellino, Laetitia ;

Hindie, Elif .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (03) :426-435

[10] Early monitoring of response to neoadjuvant chemotherapy in breast cancer with 18F-FDG PET/CT: defining a clinical aim [J].

Groheux, David ;

Giacchetti, Sylvie ;

Espie, Marc ;

Rubello, Domenico ;

Moretti, Jean-luc ;

Hindie, Elif .

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 (03) :419-425

← 1 2 →